Scotiabank Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17
Cogent Biosciences (COGT) Initiated With a Buy at Scotiabank
Cogent Biosciences Initiated at Sector Outperform by Scotiabank
Cogent Biosciences Price Target Announced at $17.00/Share by Scotiabank
Cogent Biosciences Analyst Ratings
Piper Sandler Initiates Cogent Biosciences(COGT.US) With Buy Rating, Announces Target Price $24
Cantor Fitzgerald Initiates Cogent Biosciences(COGT.US) With Buy Rating, Announces Target Price $17
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $24
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $14
Baird Maintains Cogent Biosciences(COGT.US) With Hold Rating, Maintains Target Price $8
Baird Maintains Neutral on Cogent Biosciences, Lowers Price Target to $8
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16
Needham Maintains Cogent Biosciences(COGT.US) With Hold Rating
Cogent Biosciences Analyst Ratings
Jefferies Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $20
Cogent Biosciences Price Target Cut to $14.00/Share From $17.00 by HC Wainwright & Co.
Cogent Biosciences Is Maintained at Buy by HC Wainwright & Co.
Cogent Biosciences Analyst Ratings
Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $23
Piper Sandler Sticks to Its Buy Rating for Cogent Biosciences (COGT)